Alpha Thalassemia Diagnosis in Adults: A Comprehensive Guide for Healthcare Professionals

Alpha-thalassemia is a genetic blood disorder characterized by a reduced production of alpha-globin chains, a crucial component of hemoglobin. This deficiency leads to an imbalance in globin chain synthesis, impacting red blood cell production and oxygen transport. While alpha-thalassemia can manifest across a spectrum of severities from asymptomatic carrier states to life-threatening conditions, accurate and timely Alpha Thalassemia Diagnosis In Adults is paramount for effective patient management and genetic counseling. This article provides an in-depth guide for healthcare professionals on diagnosing alpha-thalassemia in adult patients, emphasizing laboratory techniques, result interpretation, and the significance of interprofessional collaboration.

Understanding Alpha Thalassemia in Adults

Alpha-thalassemia arises from genetic mutations affecting the alpha-globin genes, of which humans typically inherit four, two from each parent. The severity of alpha-thalassemia is directly correlated with the number of affected genes. In adults, the clinical presentation can range widely. Individuals with one or two gene deletions might be asymptomatic carriers or present with mild microcytic anemia, often mistaken for iron deficiency. More severe forms, although less common in adults due to their impact on fetal viability, can still present diagnostic challenges and require specialized management.

Types of Alpha Thalassemia Relevant to Adult Diagnosis

Understanding the classification of alpha-thalassemia is crucial for accurate alpha thalassemia diagnosis in adults:

• Silent Carrier (αα/α- or αα/–): Individuals with a single alpha-globin gene deletion are typically asymptomatic. Diagnosis in adults is often incidental, through family studies or advanced genetic testing.
• Alpha-Thalassemia Trait/Minor (α-/α- or αα/–): This condition involves two alpha-globin gene deletions. Adults usually present with mild microcytic hypochromic anemia. Often misdiagnosed as iron deficiency anemia, proper alpha thalassemia diagnosis in adults is essential to avoid unnecessary iron supplementation.
• Hemoglobin H (HbH) Disease (α-/–): Resulting from three alpha-globin gene deletions, HbH disease is a more clinically significant form. Adults with HbH disease typically have moderate to severe microcytic anemia, splenomegaly, and may require intermittent transfusions. Alpha thalassemia diagnosis in adults with HbH disease relies on hemoglobin analysis to detect HbH.
• Alpha-Thalassemia Major (Hydrops Fetalis) (–/–): This most severe form, with all four alpha-globin genes deleted, is usually fatal in utero or shortly after birth. While rarely encountered in adult diagnosis in its full form, understanding this condition is important for genetic counseling when diagnosing carriers in adults.

Image alt text: Hemoglobin electrophoresis patterns illustrating common hemoglobin disorders such as Hb Bart’s, HbH, Beta Thalassemia Trait, Sickle Cell Trait and Normal Hb. This visual representation aids in differential diagnosis of hemoglobinopathies.

Diagnostic Approach for Alpha Thalassemia in Adults

The diagnostic journey for alpha thalassemia diagnosis in adults typically begins with routine hematological investigations, especially in individuals presenting with unexplained microcytic anemia. A systematic approach involving a combination of hematological, biochemical, and molecular techniques is often necessary for a definitive diagnosis.

Initial Screening Tests

• Complete Blood Count (CBC): A CBC is often the first step in alpha thalassemia diagnosis in adults. Key indicators include:

  • Hemoglobin (Hb): Usually low or low-normal, depending on the severity.
  • Mean Corpuscular Volume (MCV): Reduced (microcytic), a hallmark of alpha-thalassemia.
  • Mean Corpuscular Hemoglobin (MCH): Reduced (hypochromic), indicating decreased hemoglobin content in red blood cells.
  • Red Blood Cell (RBC) Count: Often normal or elevated, which can help differentiate thalassemia from iron deficiency anemia, where RBC count is typically low.

• Iron Studies: Crucially, iron studies are essential to differentiate alpha-thalassemia from iron deficiency anemia.

  • Serum Ferritin: Normal or elevated in thalassemia, while low in iron deficiency.
  • Transferrin Saturation: Normal in thalassemia, usually low in iron deficiency.
  • Total Iron Binding Capacity (TIBC): Normal in thalassemia, often elevated in iron deficiency.

• Peripheral Blood Smear: Microscopic examination of the peripheral blood smear can provide valuable clues for alpha thalassemia diagnosis in adults:

  • Microcytosis and Hypochromia: Small and pale red blood cells are typical.
  • Target Cells: Red blood cells with a bullseye appearance, frequently seen in thalassemia.
  • Poikilocytosis: Abnormally shaped red blood cells.
  • Basophilic Stippling: Ribosomal RNA precipitates appearing as blue granules, may be present.
  • In HbH disease, with specific staining (like brilliant cresyl blue), HbH inclusions (Heinz bodies) can be visualized, which are pathognomonic.

Image alt text: Microscopic view of a peripheral blood smear in hydrops fetalis case showing abnormal red blood cells including hypochromia, microcytosis, anisocytosis, and poikilocytosis, along with immature red cell precursors. This blood film highlights the severe hematological abnormalities in alpha-thalassemia major.

Confirmatory Diagnostic Tests

When initial screening suggests alpha-thalassemia, further confirmatory tests are necessary for definitive alpha thalassemia diagnosis in adults:

• Hemoglobin Analysis: This is a cornerstone in diagnosing hemoglobinopathies. Techniques include:
  • High-Performance Liquid Chromatography (HPLC): HPLC is highly effective in separating and quantifying different hemoglobin variants. In alpha thalassemia diagnosis in adults, HPLC can detect HbH and Hb Bart’s (though Hb Bart’s is typically in newborns, it can persist in trace amounts). It also helps quantify HbA2 and HbF, which can be normal or slightly altered in alpha-thalassemia, aiding in differentiation from beta-thalassemia.
  • Capillary Electrophoresis: Similar to HPLC, capillary electrophoresis offers high-resolution separation of hemoglobin variants based on their charge. It is a rapid and reliable method for alpha thalassemia diagnosis in adults, capable of identifying HbH, Hb Bart’s, and other abnormal hemoglobins.
  • Interpretation in Adults: In alpha-thalassemia trait, hemoglobin analysis may be normal or show a small percentage of Hb Bart’s in neonates (not typically in adults). In HbH disease, a distinct HbH peak (3-30%) will be present. Alpha-thalassemia major (Hb Bart’s hydrops fetalis) is characterized by predominantly Hb Bart’s, but this is a fetal condition.

Image alt text: Hemoglobin electrophoresis result showing the presence of HbH and Hb Bart’s fractions, indicating alpha-thalassemia major. The distinct bands of HbH and Hb Bart’s are critical markers for diagnosing severe forms of alpha-thalassemia.

• Molecular Genetic Testing: Molecular testing provides the definitive alpha thalassemia diagnosis in adults by directly identifying the genetic mutations responsible for alpha-globin gene deletions or defects.
  • Types of Molecular Tests:
    • Gap-PCR (Polymerase Chain Reaction): Detects common alpha-globin gene deletions.
    • Multiplex Ligation-dependent Probe Amplification (MLPA): Identifies deletions and duplications in the alpha-globin gene cluster, useful for detecting larger deletions or complex rearrangements.
    • Allele-Specific PCR: Detects specific point mutations or small deletions.
    • Real-Time PCR with Melting Curve Analysis: Offers rapid and quantitative detection of common mutations.
    • DNA Sequencing (Sanger Sequencing, Next-Generation Sequencing – NGS): NGS is particularly valuable for identifying rare or novel mutations and for comprehensive analysis of the alpha-globin gene cluster.
  • Clinical Utility in Adults: Molecular testing is crucial for:
    • Confirming the diagnosis, especially in ambiguous cases or silent carriers.
    • Determining the exact genotype, which is important for prognosis and genetic counseling.
    • Carrier screening in family members of affected individuals.
    • Prenatal diagnosis in subsequent pregnancies if both parents are carriers.

Differential Diagnosis in Adults

Alpha thalassemia diagnosis in adults requires careful differentiation from other conditions presenting with microcytic anemia:

• Iron Deficiency Anemia (IDA): The most common cause of microcytic anemia. Iron studies (low ferritin, low transferrin saturation, high TIBC) and response to iron supplementation are key differentiators. In alpha-thalassemia, iron stores are usually normal or increased.
• Beta-Thalassemia Trait: Can also cause microcytic anemia. Hemoglobin analysis showing elevated HbA2 is characteristic of beta-thalassemia trait, while HbA2 is typically normal or slightly decreased in alpha-thalassemia. Molecular testing can definitively distinguish between alpha and beta-thalassemia.
• Anemia of Chronic Disease: Although typically normocytic, it can sometimes be microcytic. Clinical context and inflammatory markers help differentiate it. Ferritin levels can be misleadingly normal or high in both anemia of chronic disease and thalassemia, but other iron parameters differ.
• Sideroblastic Anemia: Rare, may be microcytic or macrocytic. Bone marrow examination showing ring sideroblasts is diagnostic.

Image alt text: Flow chart illustrating the laboratory differentiation process between thalassemia and iron-deficiency anemia. Key parameters like RBC count, MCV, ferritin, and hemoglobin analysis are used in a step-wise approach to distinguish these conditions.

Interpreting Diagnostic Results in Adults

Interpreting results for alpha thalassemia diagnosis in adults requires integrating clinical findings, hematological parameters, hemoglobin analysis, and molecular genetic data.

• Silent Carrier: CBC often normal. Hemoglobin analysis normal in adults. Molecular testing reveals one alpha-globin gene deletion. Clinically asymptomatic.
• Alpha-Thalassemia Trait/Minor: Mild microcytic hypochromic anemia. RBC count normal or elevated. Hemoglobin analysis usually normal in adults. Molecular testing reveals two alpha-globin gene deletions. Mild or no clinical symptoms.
• HbH Disease: Moderate to severe microcytic anemia. HbH detected on hemoglobin analysis (HPLC or electrophoresis). HbH inclusions on peripheral smear with brilliant cresyl blue stain. Molecular testing reveals three alpha-globin gene deletions. Variable clinical severity, may require intermittent transfusions.
• Alpha-Thalassemia Major: Not typically diagnosed in adults as it’s usually fatal prenatally or neonatally. Diagnosis in a family member (e.g., parents of an affected fetus) informs carrier status and risk for future pregnancies.

Clinical Significance of Alpha Thalassemia Diagnosis in Adults

Accurate alpha thalassemia diagnosis in adults has several critical implications:

• Avoiding Misdiagnosis and Inappropriate Treatment: Prevents unnecessary iron supplementation in individuals with alpha-thalassemia trait misdiagnosed as iron deficiency anemia.
• Genetic Counseling: Enables informed genetic counseling for individuals and families, especially regarding carrier status and risks of having children with more severe forms of thalassemia.
• Management and Monitoring: Guides appropriate management strategies. Asymptomatic carriers need no treatment. HbH disease requires monitoring for anemia, splenomegaly, and potential complications like iron overload (from transfusions, if needed) or hemolysis.
• Family Screening: Diagnosis in an adult index case prompts family screening to identify other carriers and affected individuals, facilitating comprehensive genetic counseling and family planning.

Enhancing Healthcare Team Outcomes for Adult Patients

Effective alpha thalassemia diagnosis in adults and subsequent management necessitate a collaborative interprofessional healthcare team:

• Hematologist: Leads the diagnostic process, interprets complex results, and manages the hematological aspects of alpha-thalassemia.
• Laboratory Technologist: Performs and ensures the accuracy of hematological and molecular tests, playing a vital role in providing reliable diagnostic data.
• Genetic Counselor: Provides expert counseling to patients and families regarding the genetic inheritance, carrier risks, and reproductive options.
• Primary Care Physician: Often the first point of contact, recognizes potential thalassemia, initiates initial investigations, and coordinates referrals.
• Nurse Practitioner/Registered Nurse: Provides patient education, monitors clinical status, and ensures adherence to management plans.
• Pharmacist: Manages medications, including iron chelators if needed, and advises on drug interactions.

Effective communication and coordinated care among these professionals are essential to optimize outcomes for adults with alpha-thalassemia, ensuring accurate diagnosis, appropriate management, and comprehensive support for patients and their families.

Conclusion

Alpha thalassemia diagnosis in adults is a multifaceted process that requires a thorough understanding of hematological principles, laboratory techniques, and genetic interpretation. By employing a systematic diagnostic approach, incorporating CBC, iron studies, peripheral smear examination, hemoglobin analysis, and molecular testing when indicated, healthcare professionals can accurately diagnose alpha-thalassemia in adults. This accurate diagnosis is crucial not only for appropriate clinical management and avoiding misdiagnosis but also for providing essential genetic counseling and improving the quality of life for affected individuals and their families. Interprofessional collaboration is key to ensuring comprehensive and patient-centered care for adults living with alpha-thalassemia.

References
[List of references from the original article, formatted as in the original]

1.Thein SL. Molecular basis of β thalassemia and potential therapeutic targets. Blood Cells Mol Dis. 2018 May;70:54-65. [PMC free article: PMC5738298] [PubMed: 28651846]
2.Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013 May 01;3(5):a011700. [PMC free article: PMC3633182] [PubMed: 23637309]
3.Bernini LF, Harteveld CL. Alpha-thalassaemia. Baillieres Clin Haematol. 1998 Mar;11(1):53-90. [PubMed: 10872473]
4.Harewood J, Azevedo AM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 4, 2023. Alpha Thalassemia. [PubMed: 28722856]
5.Weatherall DJ. The Evolving Spectrum of the Epidemiology of Thalassemia. Hematol Oncol Clin North Am. 2018 Apr;32(2):165-175. [PubMed: 29458724]
6.Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in Laboratory Diagnosis of Thalassemia. Front Mol Biosci. 2020;7:74. [PMC free article: PMC7326097] [PubMed: 32671092]
7.Rund D. Thalassemia 2016: Modern medicine battles an ancient disease. Am J Hematol. 2016 Jan;91(1):15-21. [PubMed: 26537527]
8.Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013 Jun;98(6):833-44. [PMC free article: PMC3669437] [PubMed: 23729725]
9.Piel FB, Weatherall DJ. The α-thalassemias. N Engl J Med. 2014 Nov 13;371(20):1908-16. [PubMed: 25390741]
10.Poyart C, Wajcman H. Hemolytic anemias due to hemoglobinopathies. Mol Aspects Med. 1996 Apr;17(2):129-42. [PubMed: 8813715]
11.He S, Li J, Huang P, Zhang S, Lin L, Zuo Y, Tian X, Zheng C, Qiu X, Chen B. Characterization of Hb Bart’s Hydrops Fetalis Caused by – -SEA and a Large Novel α0-Thalassemia Deletion. Hemoglobin. 2018 Jan;42(1):61-64. [PubMed: 29493331]
12.Pang W, Long J, Weng X, Fan Q, Sun L, Pan Z, Fan Z. Identification of Three Types of α-Thalassemia Deletion, -α21.9, -α2.4, and – -THAI, and Their Frequencies, in One Family in the Population of Southern Guangxi Zhuang Autonomous Region, People’s Republic of China. Hemoglobin. 2018 Jan;42(1):37-42. [PubMed: 29447013]
13.Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a011692. [PMC free article: PMC3426822] [PubMed: 22951448]
14.Kalfa TA. Diagnosis and clinical management of red cell membrane disorders. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):331-340. [PMC free article: PMC8791164] [PubMed: 34889366]
15.Bhat VS, Dewan KK, Krishnaswamy PR. The Diagnosis of α-Thalassaemia: A Case of Hemoglobin H -α Deletion. Indian J Clin Biochem. 2010 Oct;25(4):435-40. [PMC free article: PMC2994557] [PubMed: 21966120]
16.Viprakasit V, Limwongse C, Sukpanichnant S, Ruangvutilert P, Kanjanakorn C, Glomglao W, Sirikong M, Utto W, Tanphaichitr VS. Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand. Clin Chem Lab Med. 2013 Aug;51(8):1605-14. [PubMed: 23525874]
17.King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart’s hydrops fetalis syndrome: the most severe form of α-thalassemia. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):353-360. [PMC free article: PMC6246003] [PubMed: 30504332]
18.Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol. 2013 Oct;35(5):465-79. [PubMed: 23217050]
19.Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol. 2016 May;38 Suppl 1:32-40. [PubMed: 27183541]
20.Hansson K, Schuring-Blom GH, Leschot NJ. The preserving of chorionic villi before establishing long-term cell cultures for cytogenetic analysis. Prenat Diagn. 1995 Nov;15(11):1067-9. [PubMed: 8606886]
21.Old J, Henderson S. Molecular diagnostics for haemoglobinopathies. Expert Opin Med Diagn. 2010 May;4(3):225-40. [PubMed: 23488532]
22.Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May 21;5:11. [PMC free article: PMC2893117] [PubMed: 20492708]
23.Oyaert M, Van Laer C, Claerhout H, Vermeersch P, Desmet K, Pauwels S, Kieffer D. Evaluation of the Sebia Minicap Flex Piercing capillary electrophoresis for hemoglobinopathy testing. Int J Lab Hematol. 2015 Jun;37(3):420-5. [PubMed: 25324031]
24.Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood. 2000 Jan 01;95(1):360-2. [PubMed: 10607725]
25.Liu YT, Old JM, Miles K, Fisher CA, Weatherall DJ, Clegg JB. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000 Feb;108(2):295-9. [PubMed: 10691858]
26.Rao S, Kar R, Gupta SK, Chopra A, Saxena R. Spectrum of haemoglobinopathies diagnosed by cation exchange-HPLC & modulating effects of nutritional deficiency anaemias from north India. Indian J Med Res. 2010 Nov;132(5):513-9. [PMC free article: PMC3028946] [PubMed: 21150000]
27.Kunwandee J, Srivorakun H, Fucharoen G, Sanchaisuriya K, Fucharoen S. ARKRAY ADAMS A1c HA-8180T Analyzer for Diagnosis of Thalassemia and Hemoglobinopathies Common in Southeast Asia. Lab Med. 2014 Summer;45(3):e112-21. [PubMed: 25217515]
28.Khera R, Singh T, Khuana N, Gupta N, Dubey AP. HPLC in characterization of hemoglobin profile in thalassemia syndromes and hemoglobinopathies: a clinicohematological correlation. Indian J Hematol Blood Transfus. 2015 Mar;31(1):110-5. [PMC free article: PMC4275515] [PubMed: 25548455]
29.Borbely N, Phelan L, Szydlo R, Bain B. Capillary zone electrophoresis for haemoglobinopathy diagnosis. J Clin Pathol. 2013 Jan;66(1):29-39. [PubMed: 23105123]
30.Khongthai K, Ruengdit C, Panyasai S, Pornprasert S. Analysis of Deletional Hb H Diseases in Samples with Hb A2-Hb H and Hb A2-Hb Bart’s on Capillary Electrophoresis. Hemoglobin. 2019 Jul-Sep;43(4-5):245-248. [PubMed: 31687860]
31.Suwannakhon N, Pangeson T, Seeratanachot T, Mahingsa K, Pingyod A, Bumrungpakdee W, Sanguansermsri T. Noninvasive prenatal screening test for compound heterozygous beta thalassemia using an amplification refractory mutation system real-time polymerase chain reaction technique. Hematol Rep. 2019 Sep 18;11(3):8124. [PMC free article: PMC6761473] [PubMed: 31579144]
32.Qin J, He J, Li Y, Liu N, Tao F, Zhang P, Guo W, Qin Q, Zhou W. One-step genotyping of α-thalassaemia by multiplex symmetric PCR melting curve. J Clin Pathol. 2023 Sep;76(9):632-636. [PubMed: 35701141]
33.Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O’Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG., American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013 Jul;15(7):565-74. [PMC free article: PMC3727274] [PubMed: 23788249]
34.Zhou YQ, Xiao GF, Li LY, Li WD, Liu ZY, Zhu LF, Mo QH, Qu XJ, Xu XM. Evaluation of clinical application of gap-PCR as a routine method for alpha-thalassemia carrier detection. Di Yi Jun Yi Da Xue Xue Bao. 2002 May;22(5):434-6. [PubMed: 12390707]
35.Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002 Jun 15;30(12):e57. [PMC free article: PMC117299] [PubMed: 12060695]
36.Slatko BE, Gardner AF, Ausubel FM. Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol. 2018 Apr;122(1):e59. [PMC free article: PMC6020069] [PubMed: 29851291]
37.Emms A, Castleman J, Allen S, Williams D, Kinning E, Kilby M. Next Generation Sequencing after Invasive Prenatal Testing in Fetuses with Congenital Malformations: Prenatal or Neonatal Investigation. Genes (Basel). 2022 Aug 24;13(9) [PMC free article: PMC9498826] [PubMed: 36140685]
38.Kingchaiyaphum B, Sanchaisuriya K, Fucharoen G, Chaibunruang A, Hess SY, Hinnouho GM, Barffour MA, Wessells KR, Kounnavong S, Fucharoen S. Hemoglobins F, A2 , and E levels in Laotian children aged 6-23 months with Hb E disorders: Effect of age, sex, and thalassemia types. Int J Lab Hematol. 2020 Jun;42(3):277-283. [PMC free article: PMC7318314] [PubMed: 32048804]
39.Todd D, Lai MC, Beaven GH, Huehns ER. The abnormal haemoglobins in homozygous alpha-thalassaemia. Br J Haematol. 1970 Jul;19(1):27-31. [PubMed: 5465779]
40.Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010 May 28;5:13. [PMC free article: PMC2887799] [PubMed: 20507641]
41.Curran M, Mikhael M, Sun WD, Lim J, Leung A, Morchi G, Chmait RH. Perinatal Management of Bart’s Hemoglobinopathy: Paradoxical Effects of Intrauterine, Transplacental, and Partial Exchange Transfusions. AJP Rep. 2020 Jan;10(1):e11-e14. [PMC free article: PMC6984954] [PubMed: 31993246]
42.Songdej D, Babbs C, Higgs DR., BHFS International Consortium. An international registry of survivors with Hb Bart’s hydrops fetalis syndrome. Blood. 2017 Mar 09;129(10):1251-1259. [PMC free article: PMC5345731] [PubMed: 28057638]
43.Ghosh K, Colah R, Manglani M, Choudhry VP, Verma I, Madan N, Saxena R, Jain D, Marwaha N, Das R, Mohanty D, Choudhary R, Agarwal S, Ghosh M, Ross C. Guidelines for screening, diagnosis and management of hemoglobinopathies. Indian J Hum Genet. 2014 Apr;20(2):101-19. [PMC free article: PMC4228561] [PubMed: 25400338]
44.Torcharus K, Sriphaisal T, Krutvecho T, Ketupanya A, Vuthiwong C, Suwanasophon C, Noonai A. Prenatal diagnosis of Hb Bart’s hydrops fetalis by PCR technique: Pramongkutklao experience. Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:287-90. [PubMed: 8629126]
45.Dame C, Albers N, Hasan C, Bode U, Eigel A, Hansmann M, Brenner R, Bartmann P. Homozygous alpha-thalassaemia and hypospadias–common aetiology or incidental association? Long-term survival of Hb Bart’s hydrops syndrome leads to new aspects for counselling of alpha-thalassaemic traits. Eur J Pediatr. 1999 Mar;158(3):217-20. [PubMed: 10094442]
46.Fenta DA, Ali MM. Factors Affecting Quality of Laboratory Result During Ordering, Handling, and Testing of the Patient’s Specimen at Hawassa University College of Medicine and Health Science Comprehensive Specialized Hospital. J Multidiscip Healthc. 2020;13:809-821. [PMC free article: PMC7450655] [PubMed: 32922023]
47.Kinns H, Pitkin S, Housley D, Freedman DB. Internal quality control: best practice. J Clin Pathol. 2013 Dec;66(12):1027-32. [PubMed: 24072731]
48.Laudus N, Nijs L, Nauwelaers I, Dequeker EMC. The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories. Cancers (Basel). 2022 Jul 28;14(15) [PMC free article: PMC9367251] [PubMed: 35954349]
49.Skitek M, Martinello F, Jerin A. How to Really Understand and Improve the System of Internal Quality Control and External Quality Assessment in the Accreditation Process of the Medical Laboratory? EJIFCC. 2022 Apr;33(1):23-27. [PMC free article: PMC9092718] [PubMed: 35645692]
50.Lock RJ. My approach to internal quality control in a clinical immunology laboratory. J Clin Pathol. 2006 Jul;59(7):681-4. [PMC free article: PMC1860423] [PubMed: 16803947]
51.Petersen PH, Ricós C, Stöckl D, Libeer JC, Baadenhuijsen H, Fraser C, Thienpont L. Proposed guidelines for the internal quality control of analytical results in the medical laboratory. Eur J Clin Chem Clin Biochem. 1996 Dec;34(12):983-99. [PubMed: 8986407]
52.Abu-Siniyeh A, Al-Shehri SS. Safety in Medical Laboratories: Perception and Practice of University Students and Laboratory Workers. Appl Biosaf. 2021 Sep;26(Suppl 1):S34-S42. [PMC free article: PMC9134342] [PubMed: 36032652]
53.Bayot ML, Limaiem F. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 30, 2023. Biosafety Guidelines. [PubMed: 30725895]
54.Cornish NE, Anderson NL, Arambula DG, Arduino MJ, Bryan A, Burton NC, Chen B, Dickson BA, Giri JG, Griffith NK, Pentella MA, Salerno RM, Sandhu P, Snyder JW, Tormey CA, Wagar EA, Weirich EG, Campbell S. Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future. Clin Microbiol Rev. 2021 Jun 16;34(3):e0012618. [PMC free article: PMC8262806] [PubMed: 34105993]